Natural product inhibitors of ovarian neoplasia

Phytomedicine

Volumn 10, Issue 2-3, 2003, Pages 221-232

  Silva, J S ^a   Moura, M D ^a   Oliveira, R A G ^a   Diniz, M F F ^a   Barbosa Filho, J M ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Anticancer agent; Antitumor activity; Chemotherapy; Medicinal plants; Natural products; Neoplasia; Ovarian

Indexed keywords

ALKALOID; ANTHRACENE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; CARBOHYDRATE DERIVATIVE; CAROTENOID; CINNAMOMUM CASSIA EXTRACT; DACTINOMYCIN; DITERPENE; FLAVONOID; FR 901228; HETEROCYCLIC NITRO COMPOUND; HYMENOCARDIA ACIDA EXTRACT; IRINOTECAN; LACTONE DERIVATIVE; LIGNAN DERIVATIVE; MANGIFERA INDICA EXTRACT; MYCALAMIDE A; MYCALAMIDE B; NATURAL PRODUCT; ONNAMIDE; PEPTIDE; PLANT EXTRACT; QUININE DERIVATIVE; SESQUITERPENE DERIVATIVE; SIDA RHOMBIFOLIA EXTRACT; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISCUM ALBUM EXTRACT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CINNAMOMUM CASSIA; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYMENOCARDIA ACIDA; MANGO; MEDICINAL PLANT; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SIDA RHOMBIFOLIA; VISCUM ALBUM;

CASSIA; CINCHONA PUBESCENS; CINNAMOMUM; CINNAMOMUM CASSIA; EMBRYOPHYTA; MANGIFERA; MANGIFERA INDICA; SIDA RHOMBIFOLIA; VISCUM; VISCUM ALBUM;

EID: 0037360628     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1078/094471103321659988     Document Type: Review

References (103)

1. Ahammadasahib KI, Hollingworth RM, McGovren JP, Hui YH, McLaughlin JL (1993) Mode of action of bullatacin: A potent antitumor and pesticidal annonaceous acetogenin. Life Sci 53: 1113-1120.
2. Arisawa M, Funayama S, Pezzuto JM, Kinghorn AD, Cordell GA, Farnsworth NR (1984) Potential anticancer agents. XXXII. Hydroquinone from Ipomopsis aggregata (Polemoniaceae). J Nat Prod 47: 393-394
3. Baker LH (1981) Gynecological cancers. In: Cancer and Chemotherapy (Ed Crooke ST, Prestayko AW), vol II, Academic Press, New York, 243-255
4. Baranzelli C, Bouffet E, Quintana E, Portas M, Thyss A, Patte C (2000) Non-seminomatous ovarian germ cell tumors in children. Eur J Cancer 36: 376-383
5. Bellakhdar J, Claisser R, Fleurentin J, Younos C (1991) Repertory of standard drugs in the Moroccan Pharmacopoea. J Ethnopharmacol 35: 123-143
6. Bens CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH (1990) Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol 37: 840-847
7. Bogden AE, Neil GL, Houchens DP, Ovejera AA, Sheridan MA, Johnson RK (1979) Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63: 473-476
8. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ (1998) Topotecan for the treatment of advanced epithelial ovary cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345-3352
9. Brewer M, Gershenson D, Herzog CE, Follen M, Silva EG, Taylor WJ (1999) Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17: 2670-2675
10. Burger RA, Disaia PJ, Roberts JA, Moore DH, Monk BJ (1999) Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72: 148-153
11. Burres NS, Clement JJ (1989) Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Cancer Res 49: 2935-2940
12. Cacciari N, Zaagni C, Martoni A (2000) The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer, is it possible only with peripheral blood stem cell support? Eur J Gynecol Oncol 21: 84-85
13. Cassinelli G, Geroni C, Botta B, Delle Monache G, Delle Monache F (1986) Cytotoxic and antitumor activity of vismiones isolated from Vismieae. J Nat Prod 49: 929-931
14. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ (1999) Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15: 1233-1238
15. Chabner BA, Levine AS, Johnson BL, Young RC (1978) Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 62: 429-433
16. Cheng A, Peng Z, Hong Z (1999) A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer. J West China Univ Med Sci 30: 95-98
17. Cicchetti S, Jemec B, Gault DT (2000) Two case reports of vinorelbine extravasations: Management and review of the literature. Tumori 86: 289-292
18. Coeugniet EG (1987) Assay of the cell-mediated immunity in patients with malignant and non-malignant diseases. Onkologie 10: 22-26
19. Curtin J, Barakat RR, Hoskins WJ (1994) Ovarian disease in women with breast cancer. Obstet Gynecol 84: 449-452
20. Cushman M, Mohan P (1985) Synthesis and antitumor activity of structural analogues of the anticancer benzophenanthridine alkaloid fagaronine chloride. J Med Chem 28: 1031-1036
21. Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, D'Incalci M (1992) Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 30: 459-464
22. De Furia MD (1997) Paclitaxel (Taxol®): A new natural product with major anticancer activity. Phytomedicine 4: 273-282
23. Di-Leo A (1999) New interesting medications in the treatment of ovarian cancer and in general in gynecological tumors. Tumori 85(Suppl 1): S27-S29
24. Douros JD, Suffness M (1981) New antitumor substances of natural origin. Cancer Treat Rep 8: 63-87
25. Eltabbakh GH, Yadav R (1999) Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy. Eur J Gynecol Oncol 20: 355-356
26. Ferry DR, Smith A, Malkhandi J, Fyfe DW, De Takats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668
27. Fishman A (1998) A second primary malignancy in a cohort of patients with epithelial ovarian cancer: characteristics of diagnosis. Eur J Gynecol Oncol 19: 280-283
28. Fodstad O, Olsnes S, Pihl A (1977) Inhibitory effect of abrin and ricin on the growth of transplantable murine tumors and of abrin on human cancers in nude mice. Cancer Res 37: 4559-4561
29. Fujimoto K, Oka T, Morimoto M (1987) Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res 47: 1516-1522
30. Gangadharan VP, Mathew BS, Kumar KS, Chitrathara K (1999) Primary choriocarcinoma of the ovary - Report of two cases. Indian Journal of Cancer 36: 213-215
31. Gershenson D, Burke TW, Morris M, Bast RC, Guaspari AI, Hohneker J, Wharton JT (1998) A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70: 404-409
32. Hajto T, Lanzrein N (1986) Natural killer and antibody dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 43: 93-97
33. Hassauer W, Gutsch J, Bukhardt R (1979) What prospects of success does Iscador therapy offer in advanced ovarian cancer? Onkologie 2: 28-36
34. Herrmann R (1997) Chemotherapy of malignant diseases: Where is the much-anticipated progress? Schweiz Med Wochensch 127: 2138-2139
35. Homung RI, Pearson JW, Beckwith M, Longo DI (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52: 101-107
36. Hsu B (1980) Recent progress in antineoplastic drug research in China (Review). Cancer Research in the People's Republic of China and the United States of America - Epidemiology, causation and approaches to therapy (ed Marks), Rune & Stratton, New York
37. Hsu B (1981) Pharmacology of some natural products of China. Tips 2: 271-272
38. Hu AB (1982) Ten cases of tumor treated by mainly using Cinnamomum cassia. Zhejiang-Zhongyi Zazhi 17: 60-61
39. Hu E, Ko R, Koda R, Rosen P, Jeffers S, Scholtz M, Muggia F (1990) Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol 26: 359-364
40. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stem P, Young R, Brenchley P, Chang J, Owens S, Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72: 461-468
41. Jimeno J, Faircloth G, Cameron L, Meely K, Veja E, Gómez A, Sousa-Faro JMF, Rinehart KL (1996) Pogress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs of the Future 21: 1155-1165
42. Kavanagh JJ, Gershenson DM, Copeland LJ, Wharton JT, Rutledge FN, Krakoff IH (1984) Intermittent IV homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial. Cancer Treat Rep 68: 1503-1504
43. Kawai OY, Shibata D, Niwa Y, Suzuki Y, Kajiyama H, Kitagawa T, Wakahara Y, Kakihara M, Arii Y (1999) Primary chemotherapy in strongly susected yolk sac tumor of the ovary. Int J Clin Oncol 4: 48-51
44. Kawasaki F, Takai N, Narahara H, Yokoyama S, Miyakawa I (2000) A rare case of bilateral small cell carcinoma of the ovary diagnosed during pregnancy. Int J Clin Oncol 5: 200-203
45. Kerekes P, Sharma PN, Brossi A, Chignell CF, Quinn FR (1985) Synthesis and biological effects of novel thiocolchicines. 3. Evaluation of N-acyldeacetylthiocolchicines, N-(alkoxycarbonyl) deacetylthiocolchicine and Oethyldemethylthiocolchicines. New synthesis of thiodemecolcine and antileukemic effects. J Med Chem 28: 1204-1208
46. Kerr DJ, Rustin GJ, Kaye SB, Bleehen N, Harper P, Brampton MH (1995) Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer 72: 1257-1269
47. Kinghorn AD, Balandrin MF (1993) Human medicinal agents from plants. ACS Symposium Series 534. American Chemical Society, Washington
48. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Llirata J, Tode T, Nagata I (2000) Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331
49. Koshiyama M, Fujii H, Kinezaki M, Ohgi S, Konishi M, Hidetaka N, Hayashi M, Yoshida M (2000) Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: A comparation with cisplatin. Anticancer Res 20(3A): 1353-1358
50. Kovacs E, Hajto T, Hostanska K (1991) Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer 27: 1672-1676
51. Koyama H, Katabuchi H, Tanaka N, Matsuura K, Okura H (1998) Prognosis and ovary function in patients with malignant ovarian tumors after fertility conserving surgery and chemotherapy. Jap J Fert Ster 43: 209-214
52. Lambert HE, Soutter WP (1990) Ovary, vagina and vulva. In: Treatment of cancer (Eds Sikora K, Halman KE). Chapman and Hall Medical, London, 549-561
53. Le-Donne M, Messina G, Buda C, Corrado F, Pettineo G, Salimbeni V, Irato S (1997) Intraperitoneal chemotherapy with mitoxantrone in ovary cancer. Tumori 83: 837-840
54. Lee EB, Yun HS, Woo WS (1977) Plants and animals used for fertility regulation in Korea. Korean J Pharmacog 8: 81-87
55. Leroi R (1977) Postoperative Viscum album therapy after surgery of breast neoplasms. Helv Chir Acta 44: 403-414
56. Lev LM, Posada Jr JG (1983) Aclarubicin: status of phase 1 and 2 studies in the United States. Cancer Treat Symp 1: 65-69
57. Levi J, Sharoni Y (1994) Pharmaceutical preparations containing lycopene as neoplasm inhibitor. Patent-Eur Appl-600, 544, 27pp
58. Li X, Liu L, Wu L (2000) Ifosfamide combination chemotherapy for advanced gynecologic malignancies. Zhonghua Zhongliu Zazhi 22: 330-332
59. Malfetano JH, Blessing JA, Jacobs AJ (1993) A phase II trial of didemnin B in patients with previously treated epithelial ovarian cancer. A gynecologic oncology group study. Am J Clin Oncol 6: 47-49
60. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2000) Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19: 1901-1905
61. Mattern J, Wayss K, Volm M (1984) Effect of five antineoplastic agents on tumor xenografts with different growth rates. J Nat Cancer Inst 72: 1335-1339
62. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A ginecologic oncology group study. J Clin Oncol 18: 1062-1067
63. Moura MD, Torres AR, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM (2001) Natural products inhibitors of models of mammary neoplasia. British Journal of Phytotherapy 5(3): 124-145
64. Moura MD, Silva JS, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM (2002) Natural products inhibitors of uterine cervical neoplasia. Acta Farm Bonaerense 21(1): 67-74
65. Muanza DN, Euler KL, Williams L, Newman DJ (1995) Screening for antitumor and anti-HIV activities of nine medicinal plants from Zaire. Int J Pharmacog 33: 98-106
66. Muss HB, Blessing JA, Baker VV, Barnhill DR, Adelson MD (1990) Echinomycin in advanced ovarian cancer. A phase II trial of the gynecologic oncology group. Am J Clin Oncol 13: 299-301
67. Nakata HY, Kikuch YH, Tode TH, Hirata J, Kita TK, Ishii KJ, Kudoh KY, Nagata IH, Shinomiya NY (1998) Inhibitory effects of ginsenoside rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jap J Cancer Res 89: 733-740
68. Papadimitriou CA, Moulopoulos LA, Vlahos G, Voulgaris Z, Kiosses E, Dimooulos MA (2000) Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: Long term results of a phase II study. Cancer 89: 1547-1554
69. Parker RJ, Adamson RH, Douros JD, Sieber SM (1983) Comparative pharmacologic studies of dactinomycin and pip-l-beta actinomycin. Cancer Treat Symp 1: 45-50
70. Patsner B (1998) Ovarian epithelial carcinoma metastasis to the chroid of the eye: Prolonged survival with radiation and taxol chemotherapy. Eur J Gynecol Oncol 19: 345-346
71. Peeorelli S, Wagenaar HC, Vergote IB, Curran D, Beex IVA, Wiltshaw F, Vermorken JB (1999) Cisplatin, vinblastine and bleomycin combination chemotherapy in recurrent or advanced granulosa (-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 35: 1331-1337
72. Pettit GR, Gaddamidi V, Herald DL, Singh SB, Cragg GM, Schmidt JM, Boettner FE, Williams M, Sagawa Y (1986) Antineoplastic agents. 120. Pancratium littorale. J Nat Prod 49: 995-1002
73. Pettit GR, Kamano Y, Herald CL, Fujii Y, Kizu H, Boyd MR, Boettner FE, Doubek DL, Schmidt JM, Chapuis JC, Michel C (1993) Isolation of dolastatins 10-15 from the marine mollusc Dolabella auricularia. Tetrahedron 49: 9151-9170
74. Pettit GR, Pierson FH, Herald CL (1994) Anticancer drugs from animals, plants and microorganisms. John Wiley & Sons, INC, New York
75. Pfisterer J (2000) Refinement of primary chemotherapy for advanced ovarian cancer. Onkologie 23(Suppl 2): 31-34
76. Pihl A, Fodstad O (1983) Cancerostatic lectins. Developments in Oncology 15: 134-141
77. Pihl A, Fodstad O, Olsnes S (1980) Anticancer properties of the toxic lectins abrin and ricin. Protides Biological Fluids 27: 631-636
78. Platt JS, Rogers S, Flynn EA, Taylor RR (1999) Primary angiosarcoma of the ovary: A case report and review of the literature. Gynecol Oncol 73: 443-446
79. Pratesi G, Manzotti C, Tortoreto M, Audisio RA, Zunino F (1991) Differential efficacy of flavone acetic acid against liver versus lung metastases in a human tumour xenograft. Br J Cancer 63: 71-74
80. Pujade LE, Guastalla JP, Vicent P (2000) Carbolatin in ovarian cancers. Bull Cancer Montrouge 87: 40-47
81. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM (1993) Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from fijian sponges of the genus Zyzzya. J Am Chem Soc 115: 1632-1638
82. Rinehart KL (2000) Antitumor compounds from Tunicates. Med Res Rev 20: 1-26
83. Rinehart KL, Sakai R (1995) Ecteinascidins from Ecteinascidia turbinata as neoplasm inhibitors. Patent-US5,478,932, 6 pp
84. Saha JC, Savini EC, Kasinathan S (1961) Ecbolic properties of Indian medicinal plants. Part 1. Indian J Med Res 49: 130-151
85. Schink JC, Weller E, Harris LS, Cella D, Gerstner J, Falkson C, Wadler S (2001) Outpatient taxol and carboplatin chemotherapy for suboptmially debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group phase II study (E2E93). Cancer J 7: 155-164
86. Schultze JL, Stettin A, Berg A (1991) Demonstration of a specifically aqueous mistletoe extract (Viscum album L). Klin Wochensch 69: 397-403
87. Schultze RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15: 1135-1139
88. Shimizu Y, Umezawa S, Hasumi K (1998) A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27: 650-656
89. Sreejith G, Gangadharan VP, Elizabath KA, Preetha S, Chithrathara K (2000) Primary granulocytic sarcoma of the ovary. Am J Clin Oncol 23: 239-240
90. Sumi T, Ishiko O, Yoshida H, Ogita S (2000) Bleomycin, actinomycin-D, and cisplatin treatment of ovarian germ-cell malignancies contributes to reducing adverse drug reactions. Oncol Rep 7: 1235-1238
91. Sun LC (1964) On the brew "Sheng-Hua Tang". Fu-Chien Chung-I-Yao 1: 41-42
92. Takizawa K, Satow YI, Kato Y, Kawana T (1997) Two patients with ovarian cancer refractory to cisplatin-based chemotherapy managed by new combination chemotherapy with irinotecan hydrochloride and mitomycin-C. Int J Clin Oncol 2: 238-242
93. Tanaka NG, Sakamoto N, Inoue K, Korenaga H, Kadoya S, Ogawa H, Osada Y (1989) Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res. 49: 6727-6730
94. Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I (1993) Inhibitory effects by oral administration of ginsenoside rh2 on the growth of human ovarian cancer cells in nude mice. J. Cancer Res. Clin Oncol 120: 24-26
95. Topuz E, Saip P, Aydiner A, Salihoglu Y, Berkan S, Bengisu E (1998) Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. Eur J Gynecol Oncol 19: 265-270
96. Tung TC, Lin JY, Hsu CT (1975) Some aspects on mechanism of anti-cancer activity of abrin. Toxicon 13: 127-128
97. Twu NF, Juang C, Yeng S, Lu CJ, Lai CZ, Chao KC (1999) Treatment of primary pure angiosarcoma of ovary with multiple lung metastases: A case report. Eur J Gynecol Oncol 20: 383-385
98. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antituor activities on experimental tumors in mice. J Antibiot 47: 315-423
99. Umezawa S, Shiizu Y, Takeshima N, Hasui K (1996) Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitoycin C. Int J Clin Oncol 1: 157-162
100. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Kaye SB (1999) Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17: 2069-2080
101. Yokoyama Y, Futagami M, Fukushi Y, Sakamoto T, Higuchi T, Fujii S, Sato S, Takami H, Saito Y (2000) Secondary acute nonlyphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. Arch Gynecol Obstet 263: 206-207
102. Young JA, Westlake D, Schnetzer GW, Keller AM, Sexauer JM, Newcomer LN (1985) Phase I study of divided-dose vinblastine in advanced malignancy. Cancer Treat Rep 69: 607-610
103. Zee-Cheng RKY (1997) Anticancer research on Loranthaceae plants. Drugs of the Future 22: 519-530